Triple-Drug cocktail takes on recurrent gynecologic cancers
NCT ID NCT07054567
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II study tests a combination of three drugs—BL-B01D1, pembrolizumab, and possibly bevacizumab—in people whose cervical or endometrial cancer has come back or spread. The goal is to see if the combo shrinks tumors and to find the best dose. About 96 adults aged 18–75 with recurrent or metastatic disease are being recruited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-B01D1 (izalontamab brengitecan), pembrolizumab, and bevacizumab
- What this could lead to
- If successful, this combination therapy could offer a new treatment option for people with recurrent or metastatic cervical and endometrial cancer.
- What could go wrong
- This is an early Phase II trial with only 96 participants, so results may not apply to everyone. The drugs can cause side effects, and the combination may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Hormone-Blocking drug boost chemo against cervical cancer?
- Can an antiviral make radiation more effective against cervical cancer?
- What raises endometrial cancer risk in black women? a study digs in
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?